U.S. Markets closed

Adamas Pharmaceuticals, Inc. (ADMS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.220.00 (0.00%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.22
Bid0.00 x 3000
Ask0.00 x 900
Day's Range8.18 - 8.25
52 Week Range4.02 - 9.15
Avg. Volume1,405,711
Market Cap376.369M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateFeb 21, 2022 - Feb 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.52
  • GlobeNewswire

    Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

    Acquisition strengthens Parkinson’s disease portfolio and diversifies revenue and cash flowROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). “Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue,” said Jack Khattar, President and CEO of Supern

  • GlobeNewswire

    Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

    ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus’ proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) expired at 11:59 p.m. on November 22, 2021. On October 21, 2021, Supernus and Adamas filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Com


    STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger

    NEW YORK, NY / ACCESSWIRE / November 12, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) relating to its proposed acquisition by Supernus Pharmaceuticals, Inc.